Literature DB >> 15056290

Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons.

Takashi Sasaki1, Jun Kotera, Kenji Omori.   

Abstract

Phosphodiesterase (PDE) 7B, a cAMP-specific PDE which is dominantly expressed in striatum, is expected to be involved in dopaminergic signaling in striatal neurons. Here we show, for the first time, the involvement of the dopaminergic signaling pathway in transcriptional activation of rat PDE7B in primary striatal culture. RT-PCR analysis revealed that dopamine, D1 agonist, forskolin and 8-Br-cAMP stimulation potentiated PDE7B transcription in striatal neurons, while D2 agonist failed to activate the PDE7B transcription. Pre-treatment with D1 antagonist abolished the dopamine- or D1 agonist-induced transcriptional activation of PDE7B. The activation of PDE7B transcription by these stimulators was completely ablated by pre-treatment of the cells with a cAMP-dependent protein kinase inhibitor, H-89. RT-PCR using splice variant-specific primers revealed that transcription of PDE7B1, but not of other splice variants, was activated by D1 agonist. We determined the putative transcription start site of PDE7B1, a brain-specific splice variant of PDE7B, by 5'-RACE and identified a promoter region of PDE7B1. Sequence analysis of the PDE7B1 promoter revealed the presence of a canonical cAMP-response element at 166 bp upstream of the putative transcription start site. The cAMP-responsiveness of the PDE7B1 promoter was demonstrated by functional promoter analysis using the luciferase reporter system. Deletion and mutation of the cAMP-response element site in the PDE7B1 promoter abolished the forskolin-induced activation of the PDE7B1 promoter activity. Electrophoretic mobility shift assay showed the binding of cAMP-response element binding protein to the PDE7B1 promoter. These data demonstrate the dopamine D1 receptor-mediated transcriptional activation of PDE7B through the cAMP/cAMP-dependent protein kinase/cAMP-response element binding protein pathway in striatal neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056290     DOI: 10.1111/j.1471-4159.2004.02354.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

Review 3.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 4.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

5.  A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.

Authors:  Alexander Kurz; Kay L Double; Isabel Lastres-Becker; Alessandro Tozzi; Michela Tantucci; Vanessa Bockhart; Michael Bonin; Moisés García-Arencibia; Silke Nuber; Falk Schlaudraff; Birgit Liss; Javier Fernández-Ruiz; Manfred Gerlach; Ullrich Wüllner; Hartmut Lüddens; Paolo Calabresi; Georg Auburger; Suzana Gispert
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

6.  A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia.

Authors:  Andrés Ingason; Ina Giegling; Sven Cichon; Thomas Hansen; Henrik B Rasmussen; Jimmi Nielsen; Gesche Jürgens; Pierandrea Muglia; Annette M Hartmann; Eric Strengman; Catalina Vasilescu; Thomas W Mühleisen; Srdjan Djurovic; Ingrid Melle; Bernard Lerer; Hans-Jürgen Möller; Clyde Francks; Olli P H Pietiläinen; Jouko Lonnqvist; Jaana Suvisaari; Annamari Tuulio-Henriksson; Muriel Walshe; Evangelos Vassos; Marta Di Forti; Robin Murray; Chiara Bonetto; Sarah Tosato; Rita M Cantor; Marcella Rietschel; Nick Craddock; Michael J Owen; Leena Peltonen; Ole A Andreassen; Markus M Nöthen; David St Clair; Roel A Ophoff; Michael C O'Donovan; David A Collier; Thomas Werge; Dan Rujescu
Journal:  Hum Mol Genet       Date:  2010-01-12       Impact factor: 6.150

7.  Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.

Authors:  Lingzhi Zhang; Fiona Murray; Anja Zahno; Joan R Kanter; Daisy Chou; Ryan Suda; Michael Fenlon; Laura Rassenti; Howard Cottam; Thomas J Kipps; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

8.  Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells.

Authors:  Ulrich W Laengle; Rudolf Markstein; Cecile Cazaubon; Danielle Roman
Journal:  Jpn J Ophthalmol       Date:  2009-03-31       Impact factor: 2.447

9.  Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission.

Authors:  Roberto Ciccocioppo; Giordano de Guglielmo; Hongwu Li; Miriam Melis; Lucia Caffino; Quienwei Shen; Ana Domi; Fabio Fumagalli; Gregory A Demopulos; George A Gaitanaris
Journal:  J Neurosci       Date:  2021-06-01       Impact factor: 6.167

10.  Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons.

Authors:  Yofre Cabeza-Arvelaiz; Sheila M Fleming; Franziska Richter; Eliezer Masliah; Marie-Francoise Chesselet; Robert H Schiestl
Journal:  Mol Neurodegener       Date:  2011-12-13       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.